Thrombosis and Inflammation in Acute Coronary Syndromes

Indexed in: EBSCO

Despite remarkable progress in fighting against myocardial infarction, the thrombotic complications of the coronary artery are still a significant cause of morbidity and mortality worldwide. ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Platelet Inhibitors for the Treatment of Acute Coronary Syndromes

Pp. 105-120 (16)

Hasan Gungor and Ceyhun Ceyhan


Acute coronary syndrome (ACS) is associated with significant morbidity, mortality and it is a major public health problem. The primary pathophysiological mechanism of the ACS is the response to vascular injury such as atherosclerotic plaque rupture or endothelial monolayer erosion that triggers platelet activation and aggregation leading to platelet-rich thrombi. These platelet-rich thrombi impair blood flow and result in ischemia. Inhibition of platelet aggregation by medical treatment prevents formation and progression of thrombotic process. Antiplatelet therapy is indispensible in the early and long-term management of patients with ACS. Current platelet inhibitors are thromboxane inhibitors (aspirin), P2Y12 inhibitors (ticlopidine, clopidogrel, prasugrel, ticagrelor, cangrelor and elinogrel) and protease-activated receptor antagonists (vorapaxar and atopaxar). The aim of this chapter is to discuss anti platelet therapy in ACS.


Acute coronary syndrome, antiplatelet therapy, aspirin, atherosclerosis, atoxapar, cangrelor, coronary artery disease, clopidogrel, elinogrel, inflammation, irreversible, platelets, prasugrel, protease-activated receptor, reversible, thienopyridine, thrombosis, thromboxane, ticagrelor, voraxapar.


Department of Cardiology, Adnan Menderes University, Aydın, Turkey.